CLINICAL_TRIALS ClinicalTrials.gov record update

A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05492682
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:22.053099+00:00
Published At: 2025-09-05T00:00:00+00:00
Record Updated At: 2025-09-05
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Melanoma (Skin)", "Triple-Negative Breast Cancer", "Non-Small Cell Lung Cancer", "Synovial Sarcoma", "Myxoid Liposarcoma", "Colorectal Cancer", "Osteosarcoma", "Sarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-09-05"
protocolSection.identificationModule.nctId: "NCT05492682"
protocolSection.identificationModule.officialTitle: "A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.